SJIA remains a very complex, heterogeneous, difficult-to-treat condition in many patients, particularly those with long-lasting systemic disease and/or erosive polyarthritis, who do not respond well to Il-1 and Il-6 antagonists, and those with remitting–relapsing MAS. This evidence concerns the gene IL6 and systemic-onset juvenile idiopathic arthritis.